Topical Sirolimus for Darier Disease: a Multicentre Case Series and Immunostaining of Patient Biopsies Implicating mTORC1-associated Signalling

BACKGROUND: Darier disease (DD) is caused by pathogenic ATP2A2 variants that impair calcium homeostasis and keratinocyte adhesion. Responses to MEK inhibition support investigating additional pathway-directed treatments. Phosphorylated ribosomal protein S6 (pS6) Ser240/244 provides a downstream readout of mTORC1-associated signalling. OBJECTIVES: To describe outcomes with topical sirolimus 1% in DD and quantify epidermal pS6 Ser240/244 in paired lesional and non-lesional skin and healthy controls. METHODS: We retrospectively reviewed six patients treated with compounded sirolimus 1% cream, including three who received it as an add-on to ongoing systemic therapy. Treated areas were assessed using a retrospective Physician Global Assessment (PGA). Epidermal pS6 Ser240/244 immunofluorescence was quantified in nine pairs of lesional and non-lesional DD biopsies and nine healthy-control biopsies, using one aggregate value per biopsy. RESULTS: All five evaluable patients showed symptomatic and/or clinical improvement at a median PGA assessment time of 1 month (range 10 days to 6 weeks). One patient discontinued treatment after three days because of local intolerance, precluding efficacy assessment. Mean (SD) corrected pS6 intensity was 10.3 (2.0) arbitrary units in controls, 60.0 (53.5) in non-lesional DD and 99.5 (41.2) in lesional DD. Both DD groups differed from controls (Holm-adjusted P = 0.00185 and P = 0.0000823, respectively). Non-lesional values were heterogeneous, and the paired lesional-non-lesional difference was not significant (P = 0.36). CONCLUSIONS: Topical sirolimus showed promise as a local treatment, including as an adjunct for persistent lesions during systemic therapy. Increased epidermal pS6 provides complementary biological support for investigating mTORC1 inhibition in DD.

Authors

Institutions

Publication Details

Journal
British Journal of Dermatology
Published
2026-11-12
DOI
https://doi.org/10.1093/bjd/ljag491
Primary Topic
Genetic and rare skin diseases.
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Topical Sirolimus for Darier Disease: a Multicentre Case Series and Immunostaining of Patient Biopsies Implicating mTORC1-associated Signalling

África González‐Fernández, Maria-Elena Gimeno-Ribes, Andrea Hernández-Fernández, Diego Soto‐García et al.
British Journal of Dermatology
Genetic and rare skin diseases.
article

Topical Sirolimus for Darier Disease: a Multicentre Case Series and Immunostaining of Patient Biopsies Implicating mTORC1-associated Signalling

África González‐Fernández, Maria-Elena Gimeno-Ribes, Andrea Hernández-Fernández, Diego Soto‐García, Catherine Tomé-Espiñeira, Nuria No, Or Haskel, Ignacio García-Doval, P. Dávila‐Seijo, Andrea Fernández‐Carrera, Sandra Martínez‐Fernández, Roni P. Dodiuk‐Gad, Ainhoa Rodríguez-Tébar, Cristian Sánchez-Espinel, Eulalia Baselga, Aranzazu Vergara Sánchez, María del Carmen Fraile-Alonso, M Begoña Iglesias Rodríguez
article en

Abstract

BACKGROUND: Darier disease (DD) is caused by pathogenic ATP2A2 variants that impair calcium homeostasis and keratinocyte adhesion. Responses to MEK inhibition support investigating additional pathway-directed treatments. Phosphorylated ribosomal protein S6 (pS6) Ser240/244 provides a downstream readout of mTORC1-associated signalling. OBJECTIVES: To describe outcomes with topical sirolimus 1% in DD and quantify epidermal pS6 Ser240/244 in paired lesional and non-lesional skin and healthy controls. METHODS: We retrospectively reviewed six patients treated with compounded sirolimus 1% cream, including three who received it as an add-on to ongoing systemic therapy. Treated areas were assessed using a retrospective Physician Global Assessment (PGA). Epidermal pS6 Ser240/244 immunofluorescence was quantified in nine pairs of lesional and non-lesional DD biopsies and nine healthy-control biopsies, using one aggregate value per biopsy. RESULTS: All five evaluable patients showed symptomatic and/or clinical improvement at a median PGA assessment time of 1 month (range 10 days to 6 weeks). One patient discontinued treatment after three days because of local intolerance, precluding efficacy assessment. Mean (SD) corrected pS6 intensity was 10.3 (2.0) arbitrary units in controls, 60.0 (53.5) in non-lesional DD and 99.5 (41.2) in lesional DD. Both DD groups differed from controls (Holm-adjusted P = 0.00185 and P = 0.0000823, respectively). Non-lesional values were heterogeneous, and the paired lesional-non-lesional difference was not significant (P = 0.36). CONCLUSIONS: Topical sirolimus showed promise as a local treatment, including as an adjunct for persistent lesions during systemic therapy. Increased epidermal pS6 provides complementary biological support for investigating mTORC1 inhibition in DD.

British Journal of Dermatology
Hospital Sant Joan de Déu Barcelona (ES), Technion – Israel Institute of Technology (IL), Universidad de Salamanca (ES), University of Toronto (CA), Emek Medical Center (IL), University Hospital Complex Of Vigo (ES), Hospital Universitario de Guadalajara (ES), Complejo Hospitalario de Salamanca (ES), Servicio Gallego de Salud (ES), Complejo Hospitalario de Pontevedra (ES), Universidade de Vigo (ES)
Genetic and rare skin diseases.
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon